Problem

Origami Therapeutics is addressing the lack of disease-modifying treatments for neurodegenerative diseases, beginning with Huntington’s disease (HD). HD is a hereditary, progressive disorder that damages movement, cognition, and mental health, typically during a person’s working years; as it advances, patients may require full-time care. The disease has no treatment that controls, stops, or reverses its progression, while symptomatic therapies address only parts of the burden. Its economic pain is therefore dominated by long-term caregiving, loss of independence and productivity, and the wider family burden; a systematic review identifies annual caregiver cost as a major component of HD’s economic burden.

The clearest “killer use case” is a disease-modifying therapy that reaches the brain and other affected organs, selectively removes or neutralizes mutant huntingtin, and delays the transition from early symptoms to severe disability and institutional-level care. HD is rare, with global prevalence estimated at roughly one in 15,000, but its inherited nature and well-defined genetic cause make it a particularly suitable first test of a precision neurodegeneration platform.

Product / Service

Origami is developing next-generation small-molecule protein degraders and conformation correctors rather than a marketed product or clinical service. Its degrader molecules are intended to harness the body’s natural protein-disposal machinery to selectively eliminate disease-causing proteins, while its correctors stabilize proteins in a more functional shape and prevent toxic misfolding or aggregation. The company emphasizes small molecules because they are easier to manufacture, broadly distributed in the body, and potentially capable of crossing the blood-brain barrier; the intended delivery model is therefore an oral, systemically administered medicine.

The company uses proprietary human disease models, including patient-derived neurons, to identify molecules with the best chance of clinical success. Earlier materials described an HTT degrader called ORI-113 that reduced mutant huntingtin, reduced aggregation, and improved the morphology of HD patient-derived neurons, while the January 2026 company release identifies the advancing lead as ORI-003. The broader platform is intended to expand beyond HD into Alzheimer’s, Parkinson’s, ALS, frontotemporal dementia, and other diseases involving traditionally difficult-to-drug proteins.

Market

Origami competes in the emerging targeted protein-degradation and precision-medicine segment of CNS and rare-neurodegenerative drug discovery. The opportunity is differentiated from the larger oncology-centered protein-degradation market by focusing on genetically defined neurological diseases and on targets that traditional inhibitors have struggled to address. Comparable players include Amphista Therapeutics, which is also developing CNS-active targeted protein degraders; a commercial company directory additionally lists Q Therapeutics, Bolt Biotherapeutics, Aeovian Pharmaceuticals, and Regenacy Pharmaceuticals among Origami’s competitors, although the evidence does not establish that all of these companies have directly overlapping programs.

Origami remains preclinical and research-stage, so the evidence supports a characterization of the company as pre-revenue rather than commercially launched. Its traction is scientific and partnering-oriented: it has reported human-cell and disease-model findings, joined Y Combinator’s Winter 2022 cohort, and in January 2026 entered a global collaboration and option agreement with Ipsen for a research-stage protein-degrader program. Ipsen received an exclusive option to license the program after successful candidate nomination and would assume global development and commercialization if it exercises that option, making the deal meaningful external validation but not evidence of an approved product or completed clinical proof of efficacy.